First use of Speedboat in the US

RNS Number : 1927N

Creo Medical Group PLC

16 January 2019

 

Creo Medical Group plc

("Creo" or the "Company")

First use of Speedboat in the US

 

Successful patient treatments performed by two US doctors

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces the successful first treatment of patients in the US using its Speedboat device powered by the Company's CROMA electrosurgery advanced energy platform.

As part of the Company's strategy to establish a training-centric commercialisation programme in the US two gastrointestinal surgeons from the same hospital were trained in the use of the Speedboat device over the weekend and each performed successful operations on patients this week. The two procedures were performed in both the upper and lower gastrointestinal (GI) tract respectively.

The Company expects to increase the number of trained clinicians in the US as the roll-out of the Creo Clinical Education Programme continues and looks forward to updating shareholders on further positive progress in this key market.

Speedboat is the first device developed for use with Creo's CROMA generator, an electrosurgical platform that combines bipolar radiofrequency for precise, localised cutting and microwave for controlled coagulation. The Speedboat harnesses the cut and coagulation of the generator to enable the removal of cancerous and pre-cancerous GI growths. 

Patients have now been successfully treated using the Speedboat device powered by Creo's CROMA platform in the UK, South Africa, Mainland Europe and the US.

Craig Gulliford, Creo's Chief Executive Officer, commented:

"The US is clearly a key market for the Company and the successful completion of the first procedures in the United States is another important milestone for us. Over the next few weeks and months we expect to see our Clinical Education Programme expand in the US and we will continue to update shareholders as our training-led commercialisation strategy advances."

Creo Medical Group plc
Richard Rees (CFO)	[phone]
Cenkos Securities	[phone]
Stephen Keys/Mark Connelly (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Helen Cresswell	Mob: [phone]

This announcement contains inside information.

About Creo Medical

Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy.  The Company's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy.  Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation.  This technology provides clinicians with flexible, accurate and controlled surgical solutions.

The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs.  The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures.  The Company believes its technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option of treatment.

For more information about Creo Medical please see our website, investors.creomedical.com

 

END

 

 

MSCBAMLTMBBBBBL